Antioxidant compositions comprising extracts of myrtle and rosemary

• US 8,192,767 B2
• Filed: 07/24/2007
• Issued: 06/05/2012
• Est. Priority Date: 08/04/2006
• Status: Expired due to Fees

• Current Assignee: Nuraging Biotech S.r.l.
• Original Assignee: Nuraging Biotech S.r.l.
• Inventors: Carta, Angelico
• Primary Examiner(s): MELLER, MICHAEL V
• Application Number:
  US12/376,363
• Publication Number:
  US 20100227002A1
• Time in Patent Office: 1,778 Days
• Field of Search: None
• US Class Current: 424/725
• CPC Class Codes: A23L 3/3472 Compounds of undetermined constitution obtained from animals or plants
• CPC Class Codes: A23V 2002/00 Food compositions, function of food ingredients or processes for food or foodstuffs
• CPC Class Codes: A23V 2200/02 Antioxidant
• CPC Class Codes: A23V 2250/21 Plant extracts
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 36/53 Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
• CPC Class Codes: A61K 36/61 Myrtaceae (Myrtle family), e.g. teatree or eucalyptus
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/16 for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• CPC Class Codes: A61P 25/28 for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 3/02 Nutrients, e.g. vitamins, minerals
• CPC Class Codes: A61P 3/04 Anorexiants; Antiobesity agents
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 39/06 Free radical scavengers or antioxidants
• CPC Class Codes: A61P 9/10 for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

The invention relates to a composition based on extracts of myrtle and rosemary which has been found to synergistically increase the protection of cells against pathophysiological conditions characterised and partly caused by overproduction of free radicals and to counteract the oxidative stress caused by excessive production of said free radicals, as well as for preventing and/or treating related pathologies, including apoptosis.

Claims

1. A composition consisting essentially of:

a) from approximately 1 mg to 1000 mg of an extract of myrtle (Myrtus communis) produced starting from the leaves of the myrtle by solid/liquid extraction;

b) from approximately 1 mg to 1000 mg of an extract of rosemary (Rosmarinus officinalis) produced by starting from the leaves of the rosemary by solid/liquid extraction; and

c) therapeutically effective amounts of glucosamine, curcuma and chondroitin;

wherein, the combination of a) and b) has an antioxidant potency at least 5% greater than the sum of the antioxidant potencies of a) and b) as single extracts, as measured with the 2,2-diphenyl- 1-picryl-hydrazyl (DPPH) test.

2. The composition of claim 1, wherein the combination has a potency of 15% or more higher than the sum of the single extracts of myrtle and rosemary.

3. The composition of claim 1, wherein the extract of myrtle is produced starting from dried leaves and has a reference antioxidant action observed with the DPPH test and expressed as the ability to inhibit the absorbance of DPPH by 50% (EC₅₀) at concentrations ranging from 110 to 175 mcg/ml;

wherein the extract of rosemary is produced starting from dried leaves and has a reference antioxidant action observed with the DPPH test and expressed as EC₅₀ at concentrations ranging from 5 to 35 mcg/ml.

4. The composition of claim 1, in which the (a):

(b) ratio weight-by-weight ranges from 0.1;

1000 to 1000;

0.1 for myrtle and rosemary, respectively.

5. The composition of claim 1, in a form selected from the group consisting of solid, semisolid, liquid form, tablets, lozenges, pills, capsules, granules, syrups, ampoules, drops, emulsions, suspensions, creams and gels.

6. The composition of claim 1, wherein the antioxidant potency of the combination is higher than that of the single extracts of rosemary and myrtle by about 15% to about 50%.

7. The composition of claim 1, in a form selected from the group consisting of dietary supplement, parenteral, rectal, transdermal, and topical.

10. A process of making the composition of claim 1, 8 or 9, in which the leaves of said rosemary and myrtle are subjected to solid/liquid extraction according to a method to be selected from the group consisting of:

Soxhlet extraction, maceration, percolation, ultrasound, vapour distillation, and extraction with supercritical fluids, said forms of extraction being conducted using a vegetal matrix;

solvent (weight-by-weight) ratio ranging from 1;

1 to 1;

50 and for time periods ranging from 30 minutes to 45 days in a solvent selected from the group consisting of;

water, hydroalcoholic solutions, polar organic solvents, apolar aprotic organic solvents and carbon dioxide.

11. The process of claim 10, in which the leaves of rosemary or myrtle are ground before being subjected to extraction.

12. The process of claim 10, in which the final extract obtained at the end of claim 9 is subjected to further extraction.

13. The process of claim 10, wherein the polar organic solvents are selected from the group consisting of alcohols, ketones, ethers, esters, and methylene chloride.

14. The process of claim 10, wherein said esters are selected from the group consisting of acetone, ethylene glycol, propylene glycol, diethylether, petroleum ether, and ethyl acetate.

15. The process of claim 10, wherein the apolar aprotic organic solvents are hydrocarbon solvents.

8. A composition consisting essentially of :

a) from approximately 1 mg to 1000 mg of extract of myrtle (Myrtus communis) produced starting from the leaves of myrtle by solid/liquid extraction;

b) from approximately 1 mg to 1000 mg of extract of rosemary (Rosmarinus officinalis) produced starting from the leaves of rosemary by solid/liquid extraction; and

c) therapeutically effective amounts of helichrysum and curcuma;

wherein, the combination of a) and b) has an antioxidant potency at least 5% greater than the sum of the antioxidant potencies of a) and b) as single extracts, as measured with the 2,2-diphenyl- 1-picryl-hydrazyl (DPPH) test.

9. A composition consisting essentially of:

a) from approximately 1 mg to 1000 mg of extract of myrtle (Myrtus communis) produced starting from the leaves of myrtle by solid/liquid extraction;

b) from approximately 1 mg to 1000 mg of extract of rosemary (Rosmarinus officinalis) produced starting from the leaves of rosemary by solid/liquid extraction; and

c) therapeutically effective amounts of CoQ10 and hawthorn;

wherein, the combination of a) and b) has an antioxidant potency at least 5% greater than the sum of the antioxidant potencies of a) and b) as single extracts, as measured with the 2,2-diphenyl- 1-picryl-hydrazyl (DPPH) test.